Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer

Abstract

Researchers must prioritize non-small cell lung cancer clinical research due of its high mortality. Ongoing endeavors are being made to improve the accessibility, evaluation simplicity, and prediction accuracy of endpoints in clinical studies. In this study, we investigated the correlation of the primary endpoint overall survivals (OS) with overall response rate (ORR) and progression free survival (PFS). Also, the impact of performance status (PS) was examined through spearman rank correlation. The ORR, PFS, and OS all have a strong and significant positive relationship. Spearman correlation coefficient between OS and ORR, rs = 0.697 (p < 0.0001), OS and PFS, rs = 0.765 (p < 0.0001). Any change in ORR or PFS notably affects the OS. The PS did not correlate with the endpoints, indicating poor correlation. Therefore, a larger collection of clinical trials’ endpoints is needed to better understand the relationship between endpoints.